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Summary
 
We have purified soluble mouse and human CD1d molecules to assess the structural requirements
for lipid antigen presentation by CD1. Plate-bound CD1d molecules from either species can present
the glycolipid 
 
a
 
-galactosyl ceramide (
 
a
 
-GalCer) to mouse natural killer T cells, formally dem-
onstrating both the in vitro formation of antigenic complexes, and the presentation of 
 
a
 
-GalCer
by these two CD1d molecules. Using surface plasmon resonance, we show that at neutral pH,
mouse CD1 and human CD1d bind to immobilized 
 
a
 
-GalCer, unlike human CD1b, which re-
quires acidic pH for lipid antigen binding. The CD1d molecules can also bind both to the nonan-
tigenic 
 
b
 
-GalCer and to phosphatidylethanolamine, indicating that diverse lipids can bind to
CD1d. These studies provide the first quantitative analysis of monomeric lipid antigen–CD1 in-
teractions, and they demonstrate that the orientation of the galactose, or even the nature of the
polar head group, are likely to be more important for T cell receptor contact than CD1d binding.
Key words: antigen presentation • CD1 • glycolipid • binding assay
 
T
 
he CD1 proteins are cell surface glycoproteins structur-
ally similar to MHC class I molecules, in that they con-
sist of a 43–49-kD heavy chain noncovalently associated with
a 
 
b
 
2-microglobulin (
 
b
 
2m)
 
1
 
 light chain (1). There are two
highly similar CD1 genes in mice, 
 
CD1D1
 
 and 
 
CD1D2
 
(2). The human CD1 gene family contains five members,
 
CD1A 
 
through 
 
CD1E
 
, which fall into two groups on the
basis of predicted amino acid sequence similarity (3). The
 
CD1A
 
, -
 
B
 
, and -
 
C
 
 genes comprise group I. The human,
mouse, rat, and rabbit 
 
CD1D
 
 genes comprise the second
group (3). The CD1 molecules are distinguished from the
MHC-encoded classical class I antigens by several proper-
ties, including their nonpolymorphic nature, their lack of a
requirement for a functional transporter associated with an-
tigen processing (TAP) for cell surface expression (4–8),
their endosomal localization (9–12), and their restricted tis-
sue distribution (13).
CD1 molecules probably have a unique role in the im-
mune system due to their ability to present lipid antigens to
T cells. Human group I CD1b and CD1c molecules can
present several types of lipoglycan antigens from 
 
Mycobacteria
 
species (4, 5, 14–17). Recently, mouse (m)CD1 and human
(h)CD1d have been shown to present 
 
a
 
-galactosyl cer-
amide (
 
a
 
-GalCer) to NK T lymphocytes, providing the first
evidence for lipoglycan antigen presentation by group II or
CD1d molecules (18–23). NK T cells are characterized by
expression of activating and inhibiting receptors found on
NK cells, a relatively invariant TCR, and the ability to rap-
idly produce large amounts of cytokines (24, 25). In the pres-
ence of 
 
a
 
-GalCer, the autoreactivity of NK T cells for CD1d
molecules can be greatly augmented, although 
 
b
 
-GalCer is
not antigenic (18–23). The expression of the invariant
TCR characteristic of the NK T lymphocyte subpopulation,
namely V
 
a
 
14 along with any one of several V
 
b
 
 genes in
mouse, or V
 
a
 
24 plus V
 
b
 
11 in humans, is required for a
CD1d-mediated 
 
a
 
-GalCer response (19, 20). Interestingly,
human NK T cells can recognize 
 
a
 
-GalCer presented by
mCD1, whereas mouse NK T cells recognize 
 
a
 
-GalCer plus
hCD1d (20). This high degree of conservation is consistent
with the fundamental importance of NK T cell specificity.
Although the presentation of 
 
a
 
-GalCer by CD1d mole-
cules has been well established, there are no reports on the
biochemistry of the interaction of ceramide-containing lipids
with CD1. Indeed, a phospholipid related to glycophosphati-
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
2m, 
 
b
 
2-microglobulin; GalCer, galactosyl
ceramide; DPPE, dipalmitoyl phosphatidylethanolamine; GPI, glycophos-
phatidylinositol; HA, hemagglutinin; HRP, horseradish peroxidase; mCD1,
mouse CD1.1; PEG, polyethylene glycol; RU, response unit(s); SPR, surface
plasmon resonance; TAP, transporter associated with antigen processing. 
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dylinositol (GPI) is the predominant ligand that was eluted
from mCD1 expressed by mammalian cells (26), and recently,
reactivity of some NK T cells for GPI has been demon-
strated (27). Furthermore, the quantitative study of the
binding of CD1 molecules to lipids has been hampered by
the tendency of these compounds to form insoluble aggre-
gates. Therefore, we have used purified, soluble mCD1 and
hCD1d molecules to study the biochemistry of binding and
presentation of 
 
a
 
-GalCer and several other glycolipids. To
examine monomeric CD1–lipid interactions, we used im-
mobilized derivatives of the lipids, which should be free of
aggregates or micelles. We also examined the binding of
mCD1 to a peptide ligand (28) by the surface plasmon res-
onance (SPR), and the effects of mCD1-binding lipids on
this interaction with peptide.
 
Materials and Methods
 
Chemicals.
 
The syntheses of biotinylated 
 
a
 
- and 
 
b
 
-GalCer
(biotin–
 
a
 
-GalCer and biotin–
 
b
 
-GalCer) (see Fig. 3 A) have been
described elsewhere (29). After synthesis, the biotinylated com-
pounds were purified by silica gel column, which completely re-
moved the biotinylating reagent (29). The purity of biotinylated 
 
a
 
-
and 
 
b
 
-GalCer compounds was verified by mass spectrometry. No
unbiotinylated galactosyl ceramide was detectable in the final prep-
aration of the compound (29). 
 
N
 
-(biotinoyl)dipalmitoyl-
 
l
 
-
 
a
 
-phos-
phatidylethanolamine (EZ-Link™ biotin-DPPE; see Fig. 5 A) was
purchased from Pierce Chemical Co. Gangliosides GM1 and GD1a
were purchased from Calbiochem. Hexasaccharide disialyllacto-
 
N
 
-tetraose (
 
a
 
-Neu5Ac-[2
 
®
 
3]-
 
b
 
-Gal-[1
 
®
 
3]-(
 
a
 
-Neu5Ac-[2
 
®
 
6])-
 
b
 
-GlcNac-[1
 
®
 
3]-
 
b
 
-Gal-[1
 
®
 
4]-Glc) was purchased from Sigma
Chemical Co. Polyethylene glycol (PEG)
 
2000
 
 ceramide was pur-
chased from Northern Lipids, Inc. P99 peptide (YEHDFHHIR-
EWGNHWKNCLAVM) and NH
 
2
 
 terminus biotinylated P99
peptide were synthesized at Research Genetics, Inc.
 
Gene Constructs and Transfectants.
 
For expression of soluble
hCD1d molecules in insect cells, we generated the plasmid hCD1d-
pRmHa-3, which encodes a truncated form of the hCD1d cDNA
containing 32 bp of 5
 
9
 
 untranslated region, the signal peptide
for insertion into the endoplasmic reticulum, and the cell surface
 
a
 
1–
 
a
 
3 domains. The hCD1d coding sequence was amplified us-
ing PCR from a plasmid encoding hCD1d (a gift of Dr. Steven
Balk, Beth Israel Hospital, Boston, MA). Oligonucleotides corre-
sponding to the 5
 
9
 
 untranslated region upstream of the hCD1d
AUG start codon (TTGCAGCCATGGAGGTCCCCACG) and
the distal end of the cytoplasmic domain (CGGGATCCCCAGT-
AGAGGACGATGTCCTG) introduced 5
 
9
 
 NcoI and 3
 
9
 
 BamH1
restriction enzyme sites, which allowed for cloning of the trun-
cated cDNA into a modified version of the insect cell expression
vector, pRmHa-3 (30; a gift of Dr. A. Raúl Castaño, Instituto de
Salud Carlos III, Madrid, Spain). Following the BglII cloning site
in this vector are sequences encoding 2 protein tags; the 10 amino
acid sequence, YPYDVPDYAS, derived from influenza hemagglu-
tinin (HA), which is recognized by the 7F11 mAb; and a 6-histidine
tag for protein purification on Ni-NTA agarose (Qiagen). 
 
Dro-
sophila melanogaster
 
 cells in tissue culture were cotransfected with 15
 
m
 
g of hCD1d-pRmHa-3, 15 
 
m
 
g of h
 
b
 
2m-pRmHa-3, encoding
h
 
b
 
2m, and 1 
 
m
 
g of pUChsneo by the calcium phosphate method
and selected with 1–1.5 mg/ml of G418 for 2 mo. The h
 
b
 
2m-
pRmHa construct was a gift from Dr. Jeffrey E. Miller (IVS
Technologies LLC, Carlsbad, CA).
 
Cell Lines.
 
Cultures of parental and mCD1- and hCD1d-
transfected 
 
D
 
.
 
 melanogaster
 
 embryonic SC2 cells were carried out
as described previously (31). For the culture of transfected insect
tissue culture cells, the medium was supplemented with 1 mg/ml
G418 (Sigma Chemical Co.). The mCD1-transfected 
 
D
 
.
 
 melano-
gaster 
 
cells and untransfected parental insect cell lines were a gift
of Dr. A. Raúl Castaño. The mCD1-transfected A20 cell lines
have been described previously (32).
 
Antibodies.
 
Antibodies used for ELISA were 7F11 (mouse
IgG
 
2b
 
) for detection of HA epitope–tagged polypeptides; BBM.1
for h
 
b
 
2m (33), biotinylated 1B1 (rat IgG
 
2b
 
) for mCD1 (32), and
NOR3.2 (mouse IgG
 
1
 
) for hCD1d (34). Horseradish peroxidase
(HRP)-conjugated goat anti–mouse Ig (Caltag Labs) and HRP-
conjugated streptavidin (Jackson ImmunoResearch Labs) were
used as secondary reagents in ELISA.
 
Purification of Soluble CD1d.
 
3–10 liters of insect cells, stably
cotransfected with the CD1d- and 
 
b
 
2m-encoding plasmids, were
induced with 0.7 mM CuSO
 
4
 
 for 3 d to transcribe the metallo-
thionein promoter. After induction, cell supernatant was concen-
trated and dialyzed against 0.15 M sodium phosphate buffer (pH
7.4) using
 
 
 
an Amicon Y1S10 Spiral Wound Membrane cartridge
with a 10-kD mol wt cut-off (Millipore). Soluble CD1d–
 
b
 
2m
complexes were first affinity-purified on Ni-NTA agarose column
(1 ml bed volume; Qiagen) and then FPLC purified with Mono
Q anion-exchange column (1 ml bed volume; Amersham Phar-
macia Biotech). Gel filtration was performed in PBS on
 
 
 
a Superdex
200 column (Amersham Pharmacia Biotech) to verify that purified
protein did not form aggregates. Protein concentration was de-
termined from the absorbency at 280 nm and by using the bicin-
choninic acid protein assay reagent (Pierce Chemical Co.). Solu-
ble mouse class I molecule H2-M3 was a gift of Drs. Santai Shen
and Johann Deisenhofer (Howard Hughes Medical Institute,
University of Texas, Southwestern Medical Center, Dallas, TX).
 
NK T Cell Hybridoma Stimulation.
 
The V
 
a
 
14V
 
b
 
8 NK T cell
hybridomas N38-3C3 and N38-2C12 (a gift of Dr. Kyoko Haya-
kawa, Fox Chase Cancer Center, Philadelphia, PA) and DN3A4-
1.2 (a gift of Dr. M. Bix, University of California San Francisco,
San Francisco, CA) have been described previously (19). For the
assays, T hybridoma cells were cultured for 16 h at 5 
 
3 
 
10
 
4
 
cells/well in the presence of mCD1-transfected A20 cells that had
been prepulsed for 2 h with the indicated concentrations of glyco-
lipids or with the vehicle DMSO. IL-2 release was evaluated in a
sandwich ELISA using rat anti–mouse IL-2 mAbs (PharMingen),
and the levels of cytokine release were evaluated using a recom-
binant IL-2 standard (PharMingen). For experiments in which
 
a
 
-GalCer was presented by immobilized CD1d proteins, 96-well
tissue culture plates were coated for 2 h at 37
 
8
 
C with 1 
 
m
 
g/well
of soluble protein that had been premixed with the indicated
concentrations of lipid antigen in 100 
 
m
 
l PBS. Control wells were
coated with protein only in the presence of DMSO (0.25–1% final
concentration) or with lipids alone. After coating, the plate was
washed five times in PBS and 5 
 
3
 
 10
 
4
 
 hybridoma cells/well were
added immediately. IL-2 release was measured after 16 h of cul-
ture. For competition experiments, gangliosides were dissolved in
PBS and added to CD1d proteins before the addition of 
 
a
 
-GalCer.
 
Surface Plasmon Resonance. A BIAcore X biosensor system was
used for real time binding experiments, which were all done at
room temperature. 1 mg/ml stock solutions in DMSO of biotin–
a-GalCer or biotin–b-GalCer were diluted to 50 mg/ml into
BIAcore flow buffer, Hepes-buffered saline (HBSt: 0.01 M
Hepes, pH 7.4, 0.15 M NaCl, 3.4 mM EDTA, 0.005% [vol/vol]
surfactant P20), and captured onto a streptavidin sensor chip
(BIAcore) at a flow rate of 5 ml/min, which yielded 200–400 re-1071 Naidenko et al.
sponse units (RU) of immobilized ligand. Presence of immobi-
lized biotin–a- and biotin–b-GalCer was additionally confirmed
by binding of the galactose-specific lectins Ricinus communis ag-
glutinin I (RCA I) and Isolectin B4 of Griffonia simplicifolia lectin
I (GSL I isoform B4). 0.1 mg/ml stock solution of biotin-DPPE
in DMSO was diluted to 2 mg/ml into BIAcore flow buffer for
immobilization. 2 mg/ml stock solution of biotin-P99 in water
was diluted to 20 mg/ml into BIAcore flow buffer for immobi-
lization. For biotin-GalCer, kinetic studies were performed by
injecting various concentrations of mCD1 or hCD1d in PBS or
HBSt at 10–50 ml/min flow rate to measure the association phase,
and washed with the same buffers and at the same flow rate to
measure the dissociation phase. For biotin-DPPE, kinetic studies
were done at 2 ml/min flow rate. Lipid-coupled surfaces were re-
generated using 0.5–2-min pulses of PBS containing 0.05–1%
Triton X-100 (Sigma Chemical Co.). For competition experiments,
mixtures of protein with competitor lipids were preincubated at
room temperature for 15–20 min before injection.
Estimation of Kinetic Rate Constants. Evaluation of the data was
performed using the BIAevaluation software version 2.1 (BIAcore).
For determination of the association rate constant, the association
phase of the sensogram was fitted to a single exponential model
and the kon rate was determined from the plot of the observed as-
sociation rate kobs against protein concentration, according to the
formula kobs 5 konC 1 koff. The dissociation phase of the senso-
gram was directly fitted to a single or double exponential model,
and the contribution of each component to the overall dissocia-
tion was calculated.
Results
Purification of CD1d–b2m Complexes. To biochemically
define the interaction of group II CD1 molecules with glyco-
lipids, soluble hCD1d–hb2m and mCD1–mb2m hetero-
dimers were produced in the D. melanogaster–derived SC2
cell line. This insect tissue culture system has previously been
shown to produce functional human and mouse MHC
class I, class II, and mCD1–mb2m heterodimers (28, 35,
36). CD1d heterodimers were purified to 90–99% purity
(Fig. 1 A) by nickel affinity chromatography and anion-
exchange chromatography. The identity of the CD1d mol-
ecules produced was verified in ELISA in which specific
mAbs were used to detect wells coated with the purified
proteins (Fig. 1 B). The mAbs used include the hCD1d
heavy chain–specific antibody NOR3.2, the hb2m-specific
antibody BBM.1, and the mCD1-specific antibody 1B1
(Fig. 1 B). The 7F11 antibody specific for the COOH-termi-
nal influenza HA epitope tag on the soluble heavy chains
recognized both CD1d proteins. Purified CD1d proteins
were free of aggregates, as assessed by size exclusion FPLC
chromatography (data not shown).
Immobilized CD1d Molecules Can Present a-GalCer to T
Cells. Because of the tendency of lipids to interact non-
specifically with macromolecules, we wished to determine
if physiologically relevant or antigenic lipid plus CD1d com-
plexes could be formed in vitro. Soluble mCD1 and hCD1d
molecules were preincubated with glycosphingolipids, and
were used to coat the wells of microtiter plates that were
subsequently cultured with N38-3C3 (hereafter 3C3), a
Va14/Vb81 mouse NK T cell hybridoma (19). Previously,
we demonstrated that some Va141 mouse NK T cell hybrid-
omas could recognize a-GalCer presented by either mCD1-
or hCD1d-transfected APCs (19). In agreement with those
results, we found that plate-bound mCD1 and plate-bound
hCD1d could both present a-GalCer to the 3C3 T cell hy-
bridoma, whereas plates coated with CD1d molecules with-
out antigen, or with CD1d preincubated with b-GalCer,
were not recognized (Fig. 2 A). Plates coated with the gly-
cosphingolipid antigen alone also did not stimulate the hy-
bridoma. Anti-mCD1 mAb 1B1 inhibited NK T cell rec-
ognition of a-GalCer presented by plate-bound mCD1,
but had no effect on presentation by plate-bound hCD1d
(Fig. 2 A). Thus, the T cell stimulation we observe is not
due to the reuptake of a-GalCer and mCD1-mediated auto-
presentation by the hybridoma cells, which are weakly
mCD1 positive.
The 3C3 hybridoma has a low level of autoreactivity to
mCD1-transfected A20 cells in the absence of a-GalCer
antigen (19, 20). Yet we did not observe any autoreactivity
of this hybridoma to plates coated with soluble mCD1 that
had not been preloaded with a-GalCer. The inability to
react to plate-bound mCD1 suggests that the endogenous
ligand present in soluble mCD1 molecules purified from
Drosophila cells (Degano, M., and I. Wilson, personal com-
Figure 1. Purification of soluble
CD1 proteins. (A) Coomassie blue–
stained 12% SDS polyacrylamide gel
showing FPLC-purified mCD1 and
hCD1d proteins. Molecular weight
(MW) standards are in the first lane
with sizes (in kD) indicated. (B)
ELISA confirming the identity of pu-
rified CD1d proteins. 200 ng of pro-
tein was coated per well; the blank
wells were coated with BSA only.
HRP-conjugated goat anti–mouse Ig
was used as a secondary reagent to
detect NOR3.2, BBM.1, and 7F11,
and HRP-conjugated streptavidin
was used to detect biotin-1B1. The
values represent the average of dupli-
cates of the absorbance values after
addition of the HRP substrate.1072 Galactosyl Ceramide Binding and Presentation by Soluble CD1d Molecules
munication) may be different from the endogenous ligand(s)
bound to mCD1 in A20 cells. Most interestingly, the pat-
tern of autoreactivity of two other Va141 NK T hybrid-
omas, DN3A4-1.2 (hereafter 1.2) and N38-2C12 (hereafter
2C12), to mCD1 and hCD1d molecules was recapitulated
in their autoreactivity to soluble CD1d proteins. The 1.2
hybridoma is strongly reactive to A20 hCD1d and weakly
reactive to mCD1 transfectants, even without a-GalCer
(19, 20). It also reacts to plates coated with soluble hCD1d
(Fig. 2 B), producing significant amounts of IL-2 (40 U/ml
in the experiment in Fig. 2 B; the IL-2 ELISA detection
limit is 0.1 U/ml). Similarly, 2C12 has reactivity to both
A20hCD1d and A20mCD1 transfectants without a-Gal-
Cer, and it produces IL-2 in response to plates coated with
either CD1d protein (32 U/ml for mCD1 and 9 U/ml for
hCD1d in the experiment shown in Fig. 2 B). While the
reactivity of the 1.2 and 2C12 hybridomas to the insect cell–
derived CD1d molecules is significant, this response can be
enhanced by exogenously added a-GalCer, similar to the
results with CD1d1 APCs (19, 20). Finally, Va141 mouse
NK T cell hybridomas that express either Vb7 (N38-2H4) or
Vb10 (DN3A4-1.4) TCR b chains also could recognize
a-GalCer presented by immobilized mCD1 molecules, al-
Figure 2. Immobilized purified CD1d molecules are able to present
a-GalCer to NK T cells. (A) 1 mg/well mCD1 or hCD1d proteins preincu-
bated with 100 ng of a-GalCer or b-GalCer and immobilized on a 96-well
plate was used to stimulate the T cell hybridoma, 3C3. Some wells had
antigen alone or CD1d protein alone. 15 mg/ml anti-mCD1 mAb 1B1 or
isotype control antibody (Isotype) was added to some wells immediately
before the addition of T cells. This experiment is representative of five in-
dependent experiments. (B) Stimulation of the 1.2 and 2C12 NK T cell
hybridomas by immobilized mCD1 and hCD1d proteins (1 mg/well), ei-
ther alone or with 50 ng/well of a-GalCer. This experiment is represen-
tative of five experiments.
Figure 3. Biotin-modified a-GalCer is antigenic for NK T cells. (A) Anti-
gen structures. a-GalCer is shown on the top, with the a-linkage of the sugar
indicated by an arrow and the acyl chain of the ceramide moiety enclosed
within a box. The position 1–4 carbons of the sphingosine are indicated. The
biotin-modified acyl chain of biotin–a-GalCer and biotin–b-GalCer is
shown below. (B) Biotin–a-GalCer can be recognized by NK T cells.
mCD1-transfected or control, mock-transfected A20 cells were pulsed with
100 ng/ml of lipid antigen, or with 0.1% DMSO vehicle control, washed,
and added to cultures of the 3C3 mouse NK T cell hybridoma for 16 h. IL-2
release was measured by ELISA. Data shown are from one experiment that
was repeated five times. (C) Dose-dependent stimulation of the 3C3 hybrid-
oma in response to increasing amounts of either a-GalCer or biotin–a-Gal-
Cer presented by 1 mg/well mCD1 immobilized on a microtiter plate. This
experiment is representative of three independent experiments.
though they did not show reactivity to CD1d in the ab-
sence of this antigen (data not shown).
A Biotinylated a-GalCer Derivative Is Antigenic. We syn-
thesized biotinylated versions of a-GalCer and the nonanti-
genic b-GalCer (29; Fig. 3 A) in order to develop a CD1d1073 Naidenko et al.
binding assay in which the lipid could be immobilized onto a
solid support with hydrophobic moieties exposed, thereby
minimizing the problem of micelle or bilayer formation.
The antigenicity of the biotinylated compounds was tested
using parental and mCD1-transfected A20 cells (Fig. 3 B).
mCD11 A20 cells can present both a-GalCer and the
modified biotin–a-GalCer to the 3C3 hybridoma, whereas
untransfected A20 cells could not. Other Va141 NK T cell
hybridomas could also recognize this compound (data not
shown). Biotin-modified b-linked GalCer (biotin–b-Gal-
Cer) did not stimulate the T cell hybridoma (Fig. 3 B). These
data indicate that the addition of a biotin group did not
eliminate the ability of biotin–a-GalCer to be presented by
mCD1 to NK T cells, nor did it cause b-GalCer to be rec-
ognized. However, it should be noted that the modification
of the acyl chain of this compound, including the presence
of the biotin group and two amide bonds, makes it a weaker
antigen. In dose–response experiments with mCD11 APCs,
biotin–a-GalCer gave a 1.5–2-fold lower stimulation than
the unmodified a-GalCer (data not shown). Similarly, in
antigen presentation experiments using CD1d-coated plates,
it stimulated approximately three- to fivefold lower IL-2
release when incubated with either mCD1 (Fig. 3 C) or
hCD1d molecules (data not shown).
Binding of CD1d Molecules to a- and b-GalCer. The ability
of mCD1 and hCD1d molecules to bind to biotin–a-GalCer
was examined using SPR. In our experimental set-up, bio-
tin-GalCer compounds were immobilized on flow cell 2 of
the streptavidin biosensor chip. No ligand was immobilized
on flow cell 1, which therefore provided a control surface
that allowed monitoring refractive index changes and non-
specific protein sticking. After the coupling procedure and
every protein injection, the active surface is regenerated by
washing with a solution containing Triton X-100, which
removes any noncovalently bound lipid or protein. There-
fore, binding to the exposed acyl chains of tethered a-Gal-
Cer molecules, which should be relatively free of aggre-
gates, can be directly measured. At neutral pH, soluble
Figure 4. mCD1 and hCD1d can bind to immobilized biotin–a-GalCer and biotin–b-GalCer. (A) Binding of mCD1 (0.7 mM), hCD1d (0.5 mM),
and H2-M3 (0.9 mM) to biotin–a-GalCer in PBS at 10 ml/min flow rate. I, injection; D, dissociation (washing of the chip in the running buffer). To
control for refractive index changes, the RU values for the control flow cell (Fc1) have been subtracted from the RU values for the lipid-coupled flow
cell (Fc2) to generate the sensograms shown. The noticeable dip in the binding curve during the last 20–25 s of the injection is due to the increased non-
specific sticking of the protein to flow cell 1, which generates a decreased binding signal in the subtracted (Fc2 2 Fc1) sensogram. (B) Binding of 0.04,
0.06, 0.13, 0.22, 0.33, and 0.72 mM mCD1 to immobilized biotin–a-GalCer in PBS at 50 ml/min flow rate. (A and B) Representative data from one of
three independent experiments. (C) Fitting the dissociation phase of mCD1 on biotin–a-GalCer surface to a double exponential model produces koff
fast
0.1 s21 and koff
slow 0.004 s21. The contribution of the fast component is 22%. The plot includes observed data and fitted graph. Goodness of the fit is de-
termined by the difference between the fitted values and the observed values (open symbols, plotted as Residual, RU). A residual RU with a value of less
than the noise of the instrument (63) indicates a good fit. (D) Association rate of mCD1 binding to biotin–a-GalCer surface. The slope of the plot of kobs
versus mCD1 concentration gives a kon value of 6.7 3 104 M21s21. (E) Binding of 0.13, 0.16, 0.22, 0.33, 0.5, and 1.3 mM mCD1 to immobilized biotin–
b-GalCer. All conditions were the same as in B.1074 Galactosyl Ceramide Binding and Presentation by Soluble CD1d Molecules
mCD1 and hCD1d proteins, but not H2-M3, could bind
immobilized biotin–a-GalCer (Fig. 4 A). The nonclas-
sical class Ib molecule H2-M3 was chosen as a negative
control, because, similar to mCD1, it has a hydrophobic
antigen-binding groove (37). Additionally, soluble hCD1b
protein was also able to bind to immobilized biotin-GalCer
(data not shown). mCD1 binding to biotin–a-GalCer is
dose dependent (Fig. 4 B), and similar dose–response data
were obtained using hCD1d (data not shown). Binding of
the plant lectins specific for the galactose portion of the
immobilized GalCers (GSL I-B4 and RCA I) gave a signal
similar in magnitude to the CD1d signal (29), suggesting
that CD1d molecules bound to almost all of the glyco-
sphingolipids on the chip that are accessible to macro-
molecules.
Fig. 4 C shows the dissociation curve of mCD1 from
biotin–a-GalCer. The data can be best fitted to a two-
component dissociation model with koff
fast 0.1 s21 and koff
slow
0.004 s21, which correspond to half-lives of 7 s and 3 min,
respectively. In different binding experiments, the faster
component contribution varied between 20 and 30%. We
estimated the association rate for mCD1 binding to a-Gal-
Cer from a single site model, plotting apparent association
rate constant kobs versus the concentration (Fig. 4 D). In
different experiments, kon values between 5 and 13 3 104
M21s21 were observed. By taking the weighed average of
the dissociation rate (20% 3 0.1 1 80% 3 0.004 5 0.023
s21), we obtain a KD of 0.34 mM (with the range of 5.9 3
1028 M for the slow component of dissociation to 1.5 3
1026 M for the fast component of dissociation). The calcu-
lated rate constants for hCD1d binding to a-GalCer are es-
sentially equal to those obtained for mCD1 (Table I).
It has been speculated that the a-anomeric form of the
sugar is essential for contacting the invariant NK T cell
TCR, rather than for CD1d binding (18–23). Consistent
with this hypothesis, both mCD1 and hCD1d could bind
strongly to biotin–b-GalCer (Fig. 4 E, and Table I). The
binding of b-GalCer to either mCD1 or hCD1d was sur-
prisingly similar to the binding of a-GalCer, with respect
to the two-component dissociation and the rate constants
for association and dissociation (Table I). However, in sev-
Table I. Kinetic Analyses of the Binding of Immobilized Lipids to 
Human and Mouse CD1d
CD1 Ligand kon koff (fast) koff (slow)
M21s21 s21 s21
Mouse a-GalCer 6.3 3 104 0.1 4 3 1023
Human a-GalCer 1 3 105 0.08 4 3 1023
Mouse b-GalCer 6.8 3 104 0.11 3 3 1023
Human b-GalCer 6 3 104 0.12 3 3 1023
Mouse DPPE 1.1 3 103 –3   3 1024
Human DPPE 1.4 3 103 – 2.7 3 1024
Data are representative of three experiments.
eral experiments the absolute number of RU for binding of
either CD1d molecule to the b-GalCer–coupled sensor
chips tended to be two- to threefold lower than for binding
to a-GalCer–coupled sensor chips containing approximately
the same number of RU of coupled compound (compare
Fig. 4, B and E). Thus, within the limitations of our exper-
imental set-up, it is still possible that there might be a two-
Figure 5. hCD1d binds to immobilized biotin-DPPE with slow associ-
ation and slow dissociation. (A) Structure of N-(biotinoyl)dipalmitoyl-
l-a-phosphatidylethanolamine (biotin-DPPE). (B) Binding of 1.4, 4, 5.6,
and 14 mM hCD1d to immobilized biotin-DPPE in PBS (0.005% Tween)
at 2 ml/min flow rate. (C) Fitting the association phase of hCD1d on bio-
tin-DPPE surface gives a kon value of 1.4 3 103 M21s21. The plot includes
observed data and fitted graph. Goodness of the fit is determined by the dif-
ference between the fitted values and the observed values (plotted as Resid-
ual, RU). (D) Fitting the dissociation phase of hCD1d on biotin-DPPE
surface to a single exponential model produces koff 2.7 3 1024 s21.1075 Naidenko et al.
to threefold difference in affinity between b-GalCer and
a-GalCer. However, because there is a much greater dif-
ference in the ability of b- and a-linked compounds to
stimulate mouse NK T cells, we conclude that the lack of
antigenicity of b-GalCer for NK T cells is due mainly to its
failure to properly contact the invariant Va14-containing
TCR expressed by these cells, as opposed to a drastically
reduced binding affinity for CD1d.
CD1d Binds to Phospholipids. To determine if CD1d can
bind to phospholipids, as suggested by previous studies (26,
27), we used a different biotinylated lipid, biotin-DPPE
(Fig. 5 A). This compound also permitted us to address the
effect of having two unmodified acyl chains available for
CD1d binding. Although the structure of the lipid portion
of biotin-DPPE is quite different from that of galactosyl cer-
amides, and it is not antigenic for NK T cell hybridomas
(data not shown), it is able to bind to CD1d proteins (Fig.
5 B). This binding is characterized by slower association,
kon 1.4 3 103 M21s21 (Fig. 5 C), and significantly slower
dissociation, koff 2.7 3 1024 s21 (Fig. 5 D), than binding to
immobilized biotin–a-GalCer. These on and off rates pro-
duce a calculated KD of 0.2 mM and a half-life of the CD1-
biotin–DPPE interaction of 40 min. Therefore, like human
CD1b (38), CD1d molecules can bind to diverse lipogly-
cans, although for CD1d molecules, acidic pH is not re-
quired. Furthermore, while we cannot exclude a possible
contribution of the phosphate group or some other portion
of the biotin-DPPE to the increased stability of CD1d
binding, it is most likely that availability of two uninter-
rupted acyl chains accounts for the increased half-life of
the biotin-DPPE complexes with CD1d. It probably also
accounts for the slower association rate, as interactions be-
tween the two hydrophobic acyl chains may interfere with
their loading into the separate A9 and F9 pockets of the
CD1d antigen-binding groove.
Highly Glycosylated Sphingolipids Can Compete for CD1d
Binding to Immobilized Lipids. To further demonstrate the
specificity of biotinylated sphingolipid binding to soluble
CD1d molecules, competition assays were carried out in
which CD1d molecules were preincubated in solution
with gangliosides, which are highly glycosylated sphin-
golipids. Gangliosides are not antigenic for the NK T cell
hybridomas (data not shown), presumably on account of
the b-linkage of the lipid-proximal sugar to the one carbon
of the sphingosine. However, in the micromolar concen-
tration range, gangliosides GM1 (five sugars) and GD1a (six
sugars) could inhibit mCD1 or hCD1d binding either to
biotin–a-GalCer or to biotin–b-GalCer. Representative
data are shown for the inhibition by GM1 of mCD1 and
hCD1d binding to biotin–a-GalCer in Fig. 6 A. Consis-
tent with this finding, GM1 and GD1a could inhibit pre-
sentation of a-GalCer by either plate-bound mCD1 (Fig. 6
B) or hCD1d proteins (data not shown). A control hexa-
saccharide, disialyllacto-N-tetraose, did not inhibit presen-
tation. This result indicates the importance of the ceramide
portion of gangliosides for the competition for a-GalCer
Figure 6. mCD1 can bind to both pep-
tide and glycolipid ligands. (A) GM1 inhib-
its binding of mCD1 (1.8 mM) and hCD1d
(1 mM) to the biotin–a-GalCer chip. Data
are representative of three independent ex-
periments. (B) Gangliosides GM1 and GD1a
inhibit  a-GalCer presentation by plate-
bound mCD1 to the 3C3 hybridoma,
whereas the control hexasaccharide has no
effect. 1 mg/well (0.2 mM) mCD1 was pre-
incubated with 25 ng/well a-GalCer (0.3
mM), with or without indicated concentra-
tions of competitors. (C) Binding of 2 mM
mCD1 to immobilized biotin-P99 peptide,
and competition by 0.2 and 23 mM soluble
P99 peptide. All conditions were the same
as in the legend to Fig. 4 B. (D) mCD1 (1.8
mM) binding to the biotin-P99 chip (dashed
lines) and to the biotin–a-GalCer chip
(solid line). Biotin-P99 binding is inhibited
by increasing concentrations of free P99 but
not by GM1. P99 does not affect mCD1
binding to biotin–a-GalCer. All data shown
are representative of at least three experi-
ments in each case.1076 Galactosyl Ceramide Binding and Presentation by Soluble CD1d Molecules
presentation. However, we cannot accurately estimate af-
finity constants from the CD1d–ganglioside interaction
from these competition experiments because in the micro-
molar range, gangliosides are mostly in micelles (39), with
very few monomers present. The inhibition by the gangli-
osides is most likely not due to the trapping of CD1d mol-
ecules in micelles, because CD1d molecules incubated with
the gangliosides bound as well to an anti-CD1d mAb cou-
pled to a biosensor chip as did the control CD1d molecules
(data not shown).
Sphingolipid compounds containing only a single sugar,
such as a-GalCer or b-GalCer, are much less soluble than
the gangliosides, and unlike the gangliosides, must be dis-
solved in DMSO-containing solutions. Because of their in-
solubility and the adverse effect of the DMSO upon CD1d
protein stability, we could not set up a reliable competition
assay using a- or b-GalCer mixed in aqueous solution to
compete for CD1d binding to the immobilized lipid
ligands. From these data, we infer that the increased carbo-
hydrate content of gangliosides, leading to increased solu-
bility in aqueous solutions and therefore a higher rate of
monomer formation, allows the similar lipid portions of
these molecules to compete effectively for immobilized bio-
tin-GalCer binding. Consistent with this hypothesis, we
found that ceramide coupled to a highly polar polyethylene
glycol moiety (PEG-ceramide) could also compete for
binding to immobilized biotin–a-GalCer (data not shown).
These data also underscore the importance of the ceramide
group, and demonstrate that the oligosaccharide chain of
the glycosphingolipid is not required for competition for
CD1d binding.
Noncompetitive Binding of Peptides and Lipids to mCD1. We
and others have shown that mCD1 is able to bind long hy-
drophobic peptides and present them to CD81 T cells (28,
40, 41). Using equilibrium binding studies, with radiolabeled
22-mer P99 peptide and mCD1 in solution, Castaño and
colleagues (28) estimated the mCD1 affinity for antigenic
peptide ligands to be z0.9 mM, with fast association and
dissociation kinetics. We examined mCD1 binding to immo-
bilized biotinylated P99 peptide in the BIAcore (Fig. 6 C,
and data not shown) and observed an association rate of
1–4 3 104 M21s21 and a dissociation rate of 0.005–0.008 s21.
These rates produce a calculated KD in the range of 0.2–0.8
mM, a value in good agreement with equilibrium binding
studies. The mCD1 binding to biotin-P99 was readily com-
peted by free P99 peptide (Fig. 6, C and D). Similar to the
results from peptide–MHC classical class I binding studies
(42), a peptide concentration severalfold lower than total
protein concentration resulted in a 50% inhibition of mCD1
binding. This suggests that only a percentage of the mCD1
molecules in our preparations are capable of binding the
peptide, either because of the conformational state of the
CD1d molecules, or because of some other factors such as
differential occupancy of CD1d with lipid ligands. The
binding of CD1d to immobilized P99 could not be inhib-
ited by GM1 (Fig. 6 D), suggesting that GM1 and peptide
do not bind to the same sites. Consistent with this, mCD1
binding to immobilized a-GalCer was not affected by solu-
ble P99 peptide (solid line, Fig. 6 D) at concentrations that
completely inhibited binding to immobilized peptide (dashed
line, Fig. 6 D).
Discussion
In recent years, data have been generated on lipid antigen
presentation by several different CD1 molecules (for reviews,
see references 13, 43, and 44), but there is still very little in-
formation on the biochemistry of lipid antigen binding to
CD1. The published crystallographic structure of mCD1
shows a deep, narrow, and very hydrophobic ligand-bind-
ing groove with two pockets termed A9 and F9 (45). This
analysis also shows an acyl chain containing ligand inserted
into the pockets of this groove (Degano, M., and I. Wilson,
personal communication). Mass spectrometric characteriza-
tion of the material eluted from mCD1 molecules purified
from mammalian cell lines indicated the presence of a pre-
dominant GPI ligand (26). Our in vitro binding studies have
demonstrated binding at acidic pH of phosphatidylinositol-
based compounds in solution to an hCD1b-coupled chip in
the biosensor (38). However, the signal obtained in these
studies is suggestive of multimeric antigen binding to the im-
mobilized CD1b molecules, and it remains to be determined
whether the type of binding we measured corresponds to the
formation of antigenic glycolipid–hCD1b complexes.
Here we have investigated the biochemistry of lipid anti-
gen binding to the group II molecules hCD1d and mCD1,
focusing on glycosphingolipids. These two CD1d mole-
cules are of particular interest because they are recognized
in a conserved manner by the NK T cell subset (24, 25).
The ability of NK T cells to respond to CD1d is greatly
augmented by the addition of a-GalCer, a compound iso-
lated originally from the marine sponge Agelas mauritanius,
based on its ability to prevent tumor metastases (46, 47). Gly-
cosphingolipids in mammalian cells are considered to have
only b-linked dextro-enantiomer sugar as the first sugar at-
tached to ceramide. Compounds with an a-linked dextro
sugar have not been found in mammalian cells, although it
remains possible that low levels of such compounds are
present but have not been detected. Regardless of whether
a-GalCer is the natural ligand for NK T cells or merely
cross-reactive with such a ligand, because of its ability to
stimulate a large fraction of these cells and the availability of
analogues (18–23), a-GalCer provides a very good model
for studying the CD1–glycolipid antigen interaction.
Plate-bound CD1d molecules can present a-GalCer to
NK T cell hybridomas. This demonstrates that some of the
soluble CD1d molecules are in a native conformation, which
is consistent with their ability to react with conformation-
sensitive anti-CD1d antibodies. a-GalCer can be successfully
loaded into the CD1d-binding groove at neutral pH, high-
lighting the differences in lipid binding between group I
(CD1b) and group II (CD1d) molecules, at least in terms of
acidification requirements for presentation. Although the
loading of antigen onto CD1d molecules in acidified endo-
somes is not absolutely required for stable binding and antigen
recognition (21), endosomal uptake augments the presenta-1077 Naidenko et al.
tion of a-GalCer in some circumstances (18, 21). a-GalCer–
CD1d complexes formed in vitro are physiologically rele-
vant because they can be recognized by TCRs, formally
proving that the presentation of a-GalCer is carried out by
CD1d. We were surprised to find that some of the Va141
T cell hybrids could react to a significant extent to the in-
sect cell–derived plate-bound CD1d in the absence of ex-
ogenous ligand. Our results with soluble proteins provide
one possible explanation for the CD1d autoreactivity of NK
T cell hybridomas. At least some of them could be recog-
nizing the CD1d protein directly, while the function of the
endogenous or exogenous ligand could be to maintain CD1d
molecules in proper conformation. Alternatively, it is pos-
sible that these T cells recognize the insect cell–derived
ligand when bound to CD1d.
We have used immobilized, biotinylated forms of a-Gal-
Cer and b-GalCer to demonstrate specific binding to soluble
mCD1 and hCD1d molecules. This has allowed us to ob-
tain a more quantitative estimate of the affinity of lipid CD1
binding than was possible in a previous study, since in
this case we examined the monomeric interaction between
CD1 molecules and glycolipids. As determined by SPR
studies, the affinity of both the mCD1 and hCD1d mole-
cules for galactosyl ceramides and for phospholipids is in
the 0.1–1 mM range. The near equivalence of a-GalCer
and b-GalCer binding to both mCD1 and hCD1d is estab-
lished by the results from multiple experiments. This pro-
vides the first evidence for the earlier prediction that the
sugar linkage does not significantly affect CD1d binding (18)
but is more likely to be important for TCR contact. SPR
studies also indicate that the OH groups on the 3 and 4
positions of the sphingosine (29) are likewise not required
for efficient CD1d binding (data not shown). Furthermore,
the compounds that compete effectively for CD1d binding
(Fig. 6 A) to biotin-GalCer include the gangliosides, which
lack the OH on the 4 position of the sphingosine (see Fig. 3
C for sphingosine structure), and PEG-ceramide, lacking the
hexose sugar entirely. Collectively, these data are consistent
with the hypothesis that the CD1d molecule is primarily
contacting the hydrophobic portions of the glycolipids. This
idea is additionally supported by the finding that CD1d binds
strongly to a phospholipid biotin-DPPE, which has a dis-
tinctly different polar head group. Based on these data, we
conclude that CD1d molecules are likely to be capable of
binding a variety of lipid-containing antigens.
The dissociation rate for CD1d binding to biotin–a-GalCer
predicts a half-life of several minutes, faster than what was
observed for MHC class I peptide dissociation (42, 48, 49),
although there are some exceptions from SPR experiments,
such as binding of Qa-1 protein to immobilized Qdm
peptide (50). We believe that the relatively fast off rate for
lipoglycan binding could be due to a combination of fac-
tors, including the method of attachment to the biosensor
and structural changes in the biotinylated analogue itself.
Indeed, SPR studies of MHC class I interaction with
peptide have shown that the dissociation rate is significantly
affected by both the amino acid through which the peptide
is coupled to the sensor surface and the method of coupling
(42). The sequestration of the terminal part of the acyl chain
in the streptavidin-binding pocket will prevent the acyl
chain from completely filling one of the two CD1d anti-
gen-binding pockets. Furthermore, the presence of the two
hydrophilic amide bonds in the acyl chain (Fig. 3 A) and
the presence of the biotin group at the end of it create a
suboptimal antigen (Fig. 3). Therefore, the CD1d interac-
tion with immobilized biotin-GalCer is probably limited to
a major contribution from the sphingosine only, leading to
a faster off rate. This interpretation is supported by the
longer lasting CD1d binding to immobilized biotin-DPPE,
with two unmodified lipid chains that can insert into hydro-
phobic CD1d antigen-binding pockets.
The dissociation of the peptide P99 for CD1d also has a
relatively fast off rate, similar to the off rate for CD1d bind-
ing to the immobilized sphingolipids. This is true for mea-
surements of CD1d peptide binding made in solution pre-
viously (28) as well as for measurements made with peptide
coupled to the biosensor chip through the NH2-terminal
biotin (Fig. 6) or through in an internal cysteine (data
not shown). Because of these consistent findings, the disso-
ciation is not likely to be due to modifications of the pep-
tide or details of the experimental set-up. The fast off rate is
consistent with the finding that peptide-reactive T cells re-
quire a relatively high dose of antigen, in the micromolar
range, in order to be stimulated (28, 41). The existence of
two very different kinds of mCD1-binding ligands presents a
significant biological puzzle (43). Where in the mCD1 mol-
ecule can the two types of ligands be accommodated? The
results from competition studies suggest that peptides and
lipids do not compete for the same site. This is consistent
with our earlier finding that neither P99 nor an ovalbumin
peptide could prevent a-GalCer recognition by NK T cells,
while a-GalCer did not affect ovalbumin peptide recogni-
tion by mCD1-restricted CTLs (41). Although there is
evidence that lipid binds in the groove, we can only spec-
ulate about the mechanism for peptide binding. The possi-
bilities include peptide binding outside the groove, or pep-
tide binding to the groove of a subset of CD1d molecules.
This peptide-binding CD1d subset might have a particular
posttranslational modification, or it might require particular
lipids in the groove, in which case the peptide might lie
across the top of the groove bound to CD1d and the lipid.
In conclusion, using a system in which aggregation of
the antigen is minimized, we have definitively established
and quantified by SPR the interaction of CD1d or group II
CD1 molecules with monomeric glycosphingolipids and
phospholipids. We have also demonstrated that the orienta-
tion of the sugar on the glycosphingolipid is more important
for TCR than for CD1d contact, and that CD1d binds pri-
marily to the hydrophobic acyl chains. Unlike lipid binding
to CD1b, these interactions can occur at neutral pH and
lead to the formation of antigenic CD1d–lipid complexes
in vitro. Much still remains to be learned concerning the
means by which the hydrophobic acyl chains are made
available for CD1d binding in cells, the structure of the
CD1d–lipid antigen complex, and the mechanism of pep-
tide binding to mCD1.1078 Galactosyl Ceramide Binding and Presentation by Soluble CD1d Molecules
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